Comparative Pharmacology
Head-to-head clinical analysis: PHENYTOIN SODIUM versus VIGADRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYTOIN SODIUM versus VIGADRONE.
PHENYTOIN SODIUM vs VIGADRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. Prolongs inactivation of voltage-gated sodium channels, reducing repetitive firing of action potentials.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
Loading dose: 15-20 mg/kg IV (not to exceed 50 mg/min) or oral (1000-1500 mg total in divided doses). Maintenance: 300-400 mg/day PO in 1-2 divided doses or IV (100 mg every 6-8 hours).
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
None Documented
None Documented
Mean terminal half-life 22 ± 9 hours (range 7–42 hours), dose-dependent and saturable due to Michaelis-Menten kinetics; half-life increases with higher serum concentrations. Steady state achieved after 7–10 days.
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Primarily hepatic metabolism (CYP2C9, CYP2C19); <5% excreted unchanged in urine. Metabolites (majority p-HPPA) are excreted renally as glucuronide conjugates. Fecal elimination negligible (<2%).
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Category D/X
Category C
Anticonvulsant
Anticonvulsant